The invictus study

The invictus Study

The invictus study is testing an investigational drug, DCC-2618, as a potential new treatment option for patients who have received prior anticancer therapy for GIST. The study is being done to learn more about the safety of DCC-2618 and how well it works against cancer in patients who have received prior anticancer treatments.

calendar icon

How long is the invictus study?

If you qualify to participate and choose to join the study, your participation may last up to 2 years. The actual duration will depend on a number of factors, including how your body responds to treatment and what you and the study doctor think is best for your health and well-being. Participation is always completely voluntary. You may decide to stop participation at any time, but as long as you choose to continue in the study, you must comply with all study requirements.

people icon

Who can participate in the invictus study?

Approximately 120 people will participate in the study worldwide. You may be eligible to join the study if you:

  • Are at least 18 years old
  • Have been diagnosed with GIST and received prior anticancer treatment
  • Are willing and able to comply with study procedures and restrictions

Click the "Can I participate?" button to access an invictus study pre-screener and answer a few questions to find out if you may be qualified to participate in the study.


Can I Participate?

Depending on your responses to the pre-screener questions, you may be referred to a study site for further screening assessments to determine if you can participate in the invictus study. The study doctor and staff will discuss additional criteria with you to determine if you qualify to participate.

capsule icon

What drug is being studied?

DCC-2618 is an oral medication designed to treat GIST that are growing because of changes in specific genes. Genes are the instructions that tell a part of your body called a cell what to do. Cancer changes the genes so that the instructions are no longer correct. DCC-2618 is designed to block signals from genes that cause cancer to grow. As an investigational drug, DCC-2618 has not been approved by the United States Food and Drug Administration (FDA) or any other regulatory agencies for sale or use by the public.

randomization icon

What will happen if I join the study?

You will first need to read and sign a study Informed Consent Form. During the Informed Consent process, you will have the opportunity to ask as many questions as you want about the study.

After providing written consent, you will undergo a screening process that includes tests and procedures to help determine if you qualify to participate in the study. You will also be asked about your medical history, previous anticancer treatments, medications you take, and other issues that may affect your ability to participate in the study.

Additonal Information

More details can be found at ClinicalTrials.gov (NCT03353753).

Is the invictus study an option for you or someone you know?

Find out now